Novartis announces FDA approval of Rhapsido for treatment of CSU

Novartis (NVS) announced that Rhapsido received U.S. FDA approval as an oral treatment for adult patients with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment. Rhapsido is a pill taken twice daily and does not require injections or lab monitoring. It is the first FDA-approved Bruton’s tyrosine kinase inhibitor for CSU. Rhapsido helps to inhibit the release of histamine and other proinflammatory mediators by targeting BTK, offering a unique approach to CSU treatment